593. Extended antimicrobial activity and prolonged durability of combination chlorhexidine (CHX) and minocycline/rifampin (M/R) coated vascular central venous catheters (CVC)
Session: Poster Abstract Session: Novel Antimicrobial Agents
Friday, October 21, 2011
Room: Poster Hall B1
  • 593_LauraClaburn_sm.pdf (2.1 MB)
  • Background: M/R CVCs have been shown to be efficacious in reducing catheter-related bloodstream infections with excellent inhibitory activity against biofilm formation by staphylococci and most Gram-negative bacilli.   A limitation is the lack of activity against Pseudomonas aeruginosa (PA) and Candida sp.  An improved coating was developed by sequential addition of chlorhexidine to M/R (CHX-M/R).   CHX-M/R CVCs were compared against FDA-approved M/R, CHX/Silver Sulfadiazine (CHX/SS) CVCs.

    Methods: CHX-M/R CVCs were coated for 4hr with a novel combination of CHX-M/R.  Antimicrobial durability of M/R, CHX/SS and CHX-M/R coated CVCs was determined against methicillin-resistant Staphylococcus aureus (MRSA), PA, Candida albicans (CA) and Candida glabrata (CG) by immersion for 3 weeks in serum with weekly challenges in a biofilm colonization model.

    Results: CHX-M/R had significantly more effective antimicrobial durability against MRSA and PA than the M/R, CHX/SS, and uncoated CVCs (P<0.0001) for 3 weeks (see Figure).  CHX-M/R and CHX/SS CVCs had effective antimicrobial durability against CA and CG versus M/R (data not shown below).  

    Conclusion:  CHX-M/R-CVC had prolonged antimicrobial durability and completely inhibited biofilm colonization of the multi-resistant bacteria and fungi when compared to coated M/R, CHX/SS and uncoated catheters.

    Subject Category: A. Antimicrobial agents and Resistance

    Jamal Mohamed, PhD, Anne-Marie Chaftari, MD, Ruth Reitzel, MS, Ying Jiang, MS, Tanya Dvorak, Ray Hachem, MD and Issam Raad, MD, Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX


    J. Mohamed, None

    A. M. Chaftari, None

    R. Reitzel, None

    Y. Jiang, None

    T. Dvorak, None

    R. Hachem, None

    I. Raad, Cook: Grant Investigator and Speaker's Bureau, Licensing agreement or royalty

    Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.